Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : SCRI Development Innovations, LLC | Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 27, 2013
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : SCRI Development Innovations, LLC | Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2012
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 23, 2011
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2011
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Besivance
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2011
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of Besivanceâ„¢ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
Details : Undisclosed
Product Name : Besivance
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 05, 2010
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 11, 2010
Lead Product(s) : Besifloxacin Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable